Section Arrow
Quote
IVA.NASDAQ
- Inventiva SA
Quotes are at least 15-min delayed:2025/06/02 04:01 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
3.39 
1-M High
3.89 
Volume 
1.26K 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
3 
Market Cap 
471.49M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.23 
20-SMA 3.37 
50-SMA 3.3 
52-W High 4.05 
52-W Low 1.53 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.08/-0.91
Enterprise Value
519.95M
Balance Sheet
Book Value Per Share
-0.87
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.20M
Operating Revenue Per Share
0.11
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed：2025/06/02 04:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.